| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1368698 | Bioorganic & Medicinal Chemistry Letters | 2016 | 4 Pages |
Abstract
Irritable bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C–C chemokine receptor 9 (CCR9) may be a key mediator of pro-inflammatory signaling. Discovery of agents that inhibit CCR9 may lead to new therapies for CD and UC patients. Herein we describe the evolution of a high content screening hit (1) into potent inhibitors of CCR9, such as azaindole 12.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Bhaumik A. Pandya, Christian Baber, Audrey Chan, Brian Chamberlain, Haoqun Chandonnet, Jennifer Goss, Timothy Hopper, Blaise Lippa, Katherine Poutsiaka, Jan Romero, Sabrina Stucka, Mustafa Varoglu, Jing Zhang, Xin Zhang,